Duchenne Muscular Dystrophy Market Growth
As per a study conducted by Ryder et al. titled “The burden, epidemiology, costs, and treatment for Duchenne muscular dystrophy: an evidence review,” the birth prevalence of DMD ranged from 15.9–9.5/100,000 live births. In contrast, the point prevalence per 100,000 males was found to be 10.9, 1.9, and 2.2 for France, the United States, and the United Kingdom, respectively.
In EU5 countries, the diagnosed prevalence of DMD was found to be 8,617 in 2017, which is expected to rise in the forecast period 2020–2030.
DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Duchenne Muscular Dystrophy Market, historical and forecasted epidemiology, the pipeline insight as well as the Duchenne Muscular Dystrophy market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Duchenne Muscular Dystrophy Market Growth Analysis
Duchenne Muscular Dystrophy market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in 7Mm.
The Duchenne Muscular Dystrophy market analysis section of the report helps to build a detailed comprehension of the historic, current, and forecasted Duchenne Muscular Dystrophy market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
Duchenne Muscular Dystrophy Epidemiology Forecast
The Duchenne Muscular Dystrophy epidemiology section covers insights about historical and current Duchenne Muscular Dystrophy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Duchenne Muscular Dystrophy Pipeline Analysis
The Duchenne Muscular Dystrophy Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched in the market during the study period. The analysis covers the Duchenne Muscular Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
The key companies in the Duchenne Muscular Dystrophy market include:
Sarepta Therapeutics
FibroGen
Capricor
Santhera Pharmaceutical
And others.
Duchenne Muscular Dystrophy Therapies Covered in the report includes Casimersen (SRP-4045), Givinostat (ITF2357), Edasalonexent (CAT-1004/Edasa), SRP-9001, Vamorolone, Ifetroban, and many others.
Source: Duchenne Muscular Dystrophy Market Growth